EUVIMEDEUVIMED entdecken
Vergleichsstudie

Tobramycin Pharmacokinetics in Pediatric Patients With Primary Ciliary Dyskinesia

Nathaniel J Macatangay, Samantha Engdahl, Rebecca S Pettit

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.71018 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Nathaniel J Macatangay und 2 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital, University of Missouri Health Care, Columbia, Missouri, USA. Hauptthemen laut MEDLINE: Tobramycin, Anti-Bacterial Agents, Ciliary Motility Disorders, Cystic Fibrosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with primary ciliary dyskinesia (PCD) are commonly treated for pulmonary exacerbations with intravenous tobramycin, but data on tobramycin pharmacokinetics in PCD is lacking. The objective of this study was to compare tobramycin pharmacokinetics in pediatric patients with PCD to those with cystic fibrosis (CF).

Methods

This retrospective study included pediatric patients hospitalized for a pulmonary exacerbation between January 2018 and June 2023. Included patients were treated with systemic tobramycin and had two concentrations usable to calculate patient‐specific pharmacokinetics. Each patient with PCD was matched 1:2 to patients with CF based on age. The primary outcome was tobramycin elimination rate constant.

Results

Seven patients with PCD were matched to 14 patients with CF. Baseline characteristics were similar between groups. The final tobramycin dose was not significantly different between groups (9.3 vs. 11.8 mg/kg, p = 0.192). All doses were infused over 30 min every 24 h. Tobramycin elimination rate constant (0.510 vs. 0.493 h −1 , p = 0.433) and volume of distribution (0.31 vs. 0.23 L/kg, p = 0.640) were not different between groups. No patient experienced acute kidney injury. Additionally, both groups experienced similar duration of tobramycin therapy (12.3 vs. 9.6 days, p = 0.184) and length of stay (12.0 vs. 12.6 days, p = 0.801).

Conclusions

No difference in tobramycin elimination rate constant was found between patients with PCD and those with CF. Clinical outcomes were not significantly different between groups. Although not statistically significant, a lower tobramycin dose was observed in patients with PCD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TobramycinAnti-Bacterial AgentsCiliary Motility DisordersCystic FibrosisHumansChildAdministration, IntravenousLung DiseasesRetrospective StudiesMaleFemaleChild, PreschoolAdolescentDrug Elimination Routes

Stichwörter der Autor:innen

ciliary motility disorderscystic fibrosispediatricstobramycin

Substanzen

TobramycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Children's Hospital, University of Missouri Health Care, Columbia, Missouri, USA.
  • Riley Hospital for Children, Indiana University Health, Indianapolis, Indiana, USA.

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Macatangay, N. J., Engdahl, S., & Pettit, R. S. (2025). Tobramycin Pharmacokinetics in Pediatric Patients With Primary Ciliary Dyskinesia. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71018

Vancouver

Macatangay NJ, Engdahl S, Pettit RS. Tobramycin Pharmacokinetics in Pediatric Patients With Primary Ciliary Dyskinesia. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71018

BibTeX
@article{Macatangay2025,
  author = {Macatangay, Nathaniel J and Engdahl, Samantha and Pettit, Rebecca S},
  title = {Tobramycin Pharmacokinetics in Pediatric Patients With Primary Ciliary Dyskinesia},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.71018}
}
Kostenlos starten →